This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Infectious Diseases, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A US Nationwide Prospective Survey

Boni E. Elewski, MD; James Leyden, MD; Michael G. Rinaldi, PhD; Ercem Atillasoy, MD

Arch Intern Med. 2002;162:2133-2138.

Background  Onychomycosis is sufficiently prevalent to be seen and treated by primary care physicians. The diagnosis of onychomycosis is most often confirmed from nail specimens by microscopy and fungal culture done at a central laboratory; these are relatively expensive tests with a turnaround time of a month or more. This study was conducted (1) to evaluate the use of in-office dermatophyte test medium (DTM) culture, and (2) to determine the epidemiology of onychomycosis in a large, nationwide sample of patients who were not participants in a clinical trial.

Methods  A nationwide sample of primary care physicians and podiatrists enrolled 670 patients with clinical signs of toenail onychomycosis. Dermatophyte test medium cultures were performed in the office and the results were compared with fungal cultures performed by a central laboratory.

Results  Central laboratory fungal cultures were positive in 44% (n = 297) of patients and DTM cultures in 51% (n = 345). Dermatophytes accounted for 93% of the confirmed infections and nondermatophyte molds the rest. In the 617 patients with paired dermatophyte test medium and laboratory fungal culture results, the 2 tests were in agreement (both positive or both negative) in 68% of cases (, 0.37; asymptotic SE, 0.04; 95% confidence interval, 0.299-0.441).

Conclusions  A DTM culture is a relatively rapid, easy, and inexpensive method to confirm dermatophyte infections in patients with signs of onychomycosis in the primary care setting. Because the available drugs for treating onychomycosis are effective against all dermatophyte species, the confirmation of dermatophyte infection, without further identification of genus and species, is sufficient evidence to begin treatment.

From the Department of Dermatology, University of Alabama, Birmingham (Dr Elewski); the Department of Dermatology, University of Pennsylvania Hospital, Philadelphia (Dr Leyden); the Department of Pathology, University of Texas Health Science Center at San Antonio (Dr Rinaldi); and the Departments of Dermatology, Thomas Jefferson University, Philadelphia, Pa, and Yale University School of Medicine, New Haven, Conn. (Dr Atillasoy). Dr Atillasoy was formerly a medical director of Novartis Pharmaceutical Corporation, East Hanover, NJ.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diagnosis and Prevalence of Onychomycosis in Diabetic Neuropathic Patients: An Observational Study
Dumont
J. Am. Podiatr. Med. Assoc. 2009;99:135-139.
ABSTRACT | FULL TEXT  

The pedal fungus reservoir.
Daniel and Jellinek
Arch Dermatol 2006;142:1344-1346.
FULL TEXT  

In Vitro Analysis of the Ability of Trichophyton rubrum To Become Resistant to Terbinafine
Osborne et al.
Antimicrob. Agents Chemother. 2003;47:3634-3636.
ABSTRACT | FULL TEXT  

Confirmation of Dermatophytes in Nail Specimens Using In-Office Dermatophyte Test Medium Cultures: Insights from a Multispecialty Survey
Jennings and Rinaldi
J. Am. Podiatr. Med. Assoc. 2003;93:195-202.
ABSTRACT | FULL TEXT  

Dermatophyte Test Medium Culture for Evaluating Toenail Infections in Patients With Diabetes
Rich et al.
Diabetes Care 2003;26:1480-1484.
ABSTRACT | FULL TEXT  

Evaluation of New Medium for Identification of Dermatophytes and Primary Dimorphic Pathogens
Gromadzki et al.
J. Clin. Microbiol. 2003;41:467-468.
ABSTRACT | FULL TEXT